Meridian Bioscience (VIVO) Tops Q4 EPS by 3c
Get Alerts VIVO Hot Sheet
Price: $33.97 --0%
Revenue Growth %: -100.0%
Financial Fact:
EFFECT OF DILUTIVE STOCK OPTIONS: -756K
Today's EPS Names:
SFST, VLTO, CLIR, More
Revenue Growth %: -100.0%
Financial Fact:
EFFECT OF DILUTIVE STOCK OPTIONS: -756K
Today's EPS Names:
SFST, VLTO, CLIR, More
Join SI Premium – FREE
Meridian Bioscience (NASDAQ: VIVO) reported Q4 EPS of $0.23, $0.03 better than the analyst estimate of $0.20. Revenue for the quarter came in at $76.2 million versus the consensus estimate of $68.4 million.
GUIDANCE:
Meridian Bioscience sees FY2022 EPS of $0.98-$1.08, versus the consensus of $1.63. Meridian Bioscience sees FY2022 revenue of $285-300 million, versus the consensus of $310 million.
For earnings history and earnings-related data on Meridian Bioscience (VIVO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lockheed Martin (LMT) Tops Q1 EPS by 53c, Beats on Revenue; Offers FY24 Guidance
- Fisker (FSR) files form 10-K, sees more job cuts, reiterates going concern doubts
- NextEra Energy (NEE) Tops Q1 EPS by 16c, provides guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!